Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.78 |
| ▸ | POLB | P06746 | 7/20 | 0.78 |
| ▸ | MAPT | P10636 | 6/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.78 |
| ▸ | STAT1 | P42224 | 1/20 | 0.78 |
| ▸ | RAB9A | P51151 | 1/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
| ▸ | GLA | P06280 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.56 |
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853686 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL18880260 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL26780129 | 0.86 | PDE2A (0.65) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL26768218 | 0.86 | KDM4E (0.60) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL26780127 | 0.86 | MAPT (0.72) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL20581955 | 0.86 | KDM4E (0.59) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL7859300 | 0.86 | ALDH1A1 (0.72) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL26768171 | 0.84 | MAPT (0.59) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL26577390 | 0.84 | ALDH1A1 (0.70) | KDM4EALDH1A1POLBMAPTNPC1 | |
| SCHEMBL29853651 | 0.84 | ALDH1A1 (0.55) | KDM4EALDH1A1POLBMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-RE46558-E1 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381187-B2 | Radiation countermeasure agents | PALOMA PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015154047-A1 | NOVEL METHODS | RESTORGENEX CORPORATION (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2014-08-07 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS INC (US) | 2014-04-17 | — | — | US | disclosed |
| US-8475776-B2 | Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2364700-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | Paloma Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | PALOMA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | PALOMA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2007101247-A2 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | PALOMA PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | PALOMA PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268679-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | KDM4E 1817/4885ALDH1A1 2351/4885POLB 233/4885 |
| US-20140221471-A1 | COMPOSITIONS AND METHODS TO TREAT SKIN DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, TYR | KDM4E 1817/4885ALDH1A1 2351/4885POLB 233/4885 |
| US-20140105920-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASE CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, FLT1 | KDM4E 3557/4885ALDH1A1 1226/4885POLB 812/4885 |
| US-20110021618-A1 | METHODS OF TREATING FIBROTIC DISORDERS | COL2A1, MMP1, COL1A1 | KDM4E 2823/4885ALDH1A1 494/4885POLB 1815/4885 |
| US-20070197567-A1 | COMPOSITIONS AND METHODS TO TREAT DISEASES CHARACTERIZED BY CELLULAR PROLIFERATION AND ANGIOGENESIS | MKI67, VEGFA, HDGF | KDM4E 3839/4885ALDH1A1 1225/4885POLB 938/4885 |
| US-20060257337-A1 | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis | MKI67, VEGFA, TYR | KDM4E 1817/4885ALDH1A1 2351/4885POLB 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.